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Synaptopathies are brain disorders characterized by dysfunctional synapses,
which are specialized junctions between neurons that are essential for the trans-
mission of information. Synaptic dysfunction can occur due to mutations that
alter the structure and function of synaptic components or abnormal expression
levels of a synaptic protein. One class of synaptic proteins that are essential to
their biology are cell adhesion proteins that connect the pre- and post-synaptic
compartments. Neurexins are one type of synaptic cell adhesion molecule that
have, recently, gained more pathological interest. Variants in both neurexins
and their common binding partners, neuroligins, have been associated with
several neuropsychiatric disorders. In this review, we summarize some of the
key physiological functions of the neurexin protein family and the
protein networks they are involved in. Furthermore, examination of published
literature has implicated neurexins in both neuropsychiatric and neuro-
degenerative disorders. There is a clear link between neurexins and
neuropsychiatric disorders, such as autism spectrum disorder and schizo-
phrenia. However, multiple expression studies have also shown changes in
neurexin expression in several neurodegenerative disorders, including
Alzheimer’s disease and Parkinson’s disease. Therefore, this review highlights
the potential importance of neurexins in brain disorders and the importance of
doing more targeted studies on these genes and proteins.1. Introduction
There is accumulating evidence to suggest that synaptic dysfunction is present
in both neuropsychiatric disorders, such as autism spectrum disorders (ASDs),
schizophrenia and bipolar disorder (BD), and neurodegenerative disorders,
such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and Huntington’s
disease (HD) [1]. In fact, involvement of the synapse is such a prominent feature
of the pathogenesis of various brain disorders that it has led to the coining of a
specific term, ‘synaptopathies’. Indeed, in the case of PD, the involvement of
synaptopathy as an initial and central event in the disease pathogenesis,
which precedes neuronal damage, has been postulated [2]. Synaptic dysfunc-
tion can occur due to mutations that alter the structure and function of
synaptic components or abnormal expression levels of a synaptic protein.
Synapses are specialized junctions between neurons that transmit information
and they connect neurons into millions of ‘neural circuits’ that underlie all brain






























Figure 1. Location of neurexins and their binding partners, neuroligins, in
the synapse. Several neurexin–neuroligin pathway proteins are shown as
well as synaptic vesicle-binding proteins. NMDAR, N-methyl-D-aspartate
receptor; mGluR5, metabolic glutamate receptor 5; PSD-95, post-synaptic



















































to external stimuli and controls bodily functions, behaviour,
emotions and memories [4]. This system is tightly controlled
and regulated, and even slight perturbations can lead to synap-
tic dysfunction. An important aspect of synapse biology is the
cell adhesion molecules that connect pre- and post-synaptic
compartments [5]. These interactions in the synaptic cleft
help to maintain synapse structure by delineating mutual
boundaries [6]. These proteins are also important in synapse
plasticity as synaptic cell adhesion is able to regulate the remo-
delling of synapses [7]. Interestingly, they are also involved
in trans-synaptic signalling [5]. Thus, these proteins are
highly important in the organization of synaptic junctions
and overall brain function.
Neurexins are one type of synaptic cell adhesion molecule.
They are pre-synaptically localized and bind to neuroligins and
other proteins in the post-synapse (figure 1). Neurexins and
their common binding partners, neuroligins, have recently
gained more pathological interest as variants in both have
been associated with several neuropsychiatric disorders,
including autism and schizophrenia [8]. This further suggests
that synaptic dysfunction plays a role in the development of
these disorders. Synaptic dysfunction is also known to occur
in neurodegenerative disorders [9]; however, it was considered
an endpoint of these disorders, due to the considerably later
onset of clinical symptoms and progressive appearance of cog-
nitive deficits. This dichotomy has, recently, been challenged
by the creation of ‘disease-in-a-dish’ models for multiple cen-
tral nervous system (CNS) pathologies [9]. This research
has identified commonalities between developmental and
degenerative disorders, at both the cellular and molecular
level, with most of these common mechanisms meeting at
the synapse level [9]. Indeed, our laboratory has, recently,
found a novel variant (p.G849D) in the NRXN2 gene which
may be implicated in PD [10]. Therefore, we believe it is impor-
tant to investigate the potential role of neurexins in various
neuropsychiatric and neurodegenerative disorders.
In this review, we summarize some of the key physiologi-
cal functions of the neurexin protein family and the protein
networks they are involved in. We also examine the available
published literature to determine what research has been
done on neurexins in neuropsychiatric and neurodegenera-
tive disorders. This analysis provides an overview on what
progress has been made in understanding the roles of synap-
tic functioning in these disorders and reveals the gaps in
knowledge in this field.Figure 2. Structural domain organization of the α and β forms of neurexin.
(a) α-neurexin. (b) β-neurexin. EGF, epidermal growth factor-like region; LNS,
laminin/neurexin/sex hormone-binding domain; PDZ, PSD-95, DLG1, ZO-1
domain; SP, signal peptide; TM, transmembrane domain.2. Structure and biological functions of
neurexins
Neurexins were first identified using affinity chromatography
when neurexin 1α was found in rat brain extract on a column
of α-latrotoxin [11]. α-latrotoxin is a potent neurotoxin from
black widow spider venom that stimulates synaptic vesicle
exocytosis and induces massive neurotransmitter release
[12]. This work has been continued by Südhof and co-
workers [13] who have characterized the neurexin proteins
and their binding partners, the neuroligins [14].
In mammals, the neurexins are encoded by three NRXN
genes (NRXN1-3), each of which has both an upstream promo-
ter that is used to generate the α-neurexins, and a downstream
promoter that is used to generate the shorter β-neurexins
[13,15]. Neurexins also undergo extensive alternate splicingat five splice sites, generating significant diversity of more
than 2000 potential variants [13,16]. The fact that neurexin
splice insert sequences and their positions are well conserved
among neurexin genes and between species supports the
idea that alternative splicing has important functional roles.
The neurexins are transmembrane proteins that consist
of an extracellular region responsible for trans-synaptic
interactions, a transmembrane domain and a smaller cyto-
plasmic domain named PSD-95, DLG1, ZO-1 binding
domain (PDZ) that is involved in intracellular protein inter-
actions and signalling (figure 2) [13]. α-neurexins are
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bar chart of biological process categories bar chart of cellular component categories bar chart of molecular function categories(b)(a) (c)
Figure 3. A summary of GO terms associated with neurexins 1–3. (a) Biological processes. (b) Cellular components. (c) Molecular functions. All: total number of









































hormone-binding (LNS) globulin domains with three
interspersed epidermal growth factor (EGF)-like regions
(figure 2). β-neurexins are shorter and only have the sixth extra-
cellular LNS domain and no EGF-like regions (figure 2). Only
neurexin 1 protein structures (both α and β forms) have been
solved experimentally in Mus musculus, Rattus norvegicus and
Bos taurus. However, these structures have not yet been
solved in humans.
Neurexins are localized pre-synaptically and are distribu-
ted to both excitatory and inhibitory synapses [8]. Their
functions are mediated by their binding to neuroligins
(figure 1). Neuroligins have five known isoforms and are
expressed post-synaptically [17]. Consequently, neurexins
and neuroligins form synaptic complexes in the synaptic
cleft and have been found to control synapse formation,
maturation, validation and function [17]. Various combi-
nations of the different neurexins and neuroligin binding
partners at synapses may also help determine synapse speci-
ficity through differential interactions between multiple
splice variants and isoforms of these proteins [8].
Primarily, neurexins function to maintain synaptic organiz-
ation. Gene ontology (GO) analysis by WebGestalt (http://
www.webgestalt.org) [18] of the three neurexins indicates that
they all function in protein binding, ion binding and possess
molecular transducer activity (figure 3). They are also involved
in cellular component organization, developmental processes,
response to stimuli, cell communication and biological regu-
lation. These processes thus demonstrate how neurexins are
able to maintain synaptic organization but also show their
multi-functional nature. As such, it is conceivable that disrup-
tions in neurexins could be detrimental to their various
functions and affect overall neuronal function and integrity.3. Biological pathways and interacting
partners of neurexins
To understand the broader biological pathways that the neur-
exins are involved in, protein–protein interaction networkanalysis and co-expression analysis was performed using the
tools, STRING (https://string-db.org) [19] and GeneMania
(https://genemania.org) [20]. STRING finds related genes by
accessing the STRING database which contains experimental
data and computational predictions. Data in STRING are
weighted and integrated and a confidence score of 0–1 is calcu-
lated for all interacting protein partners. GeneMANIA finds
proteins related to neurexins by leveraging functional associ-
ation data, such as interactions, pathways, co-expression, co-
localization and protein domain similarity. All functional
data for the proteins observed in these networks were obtained
from UniProt (https://www.uniprot.org) [21], unless other-
wise stated, while pathway data were obtained from KEGG
(https://www.kegg.jp) [22].3.1. String analysis
Weighted string analysis was conducted on neurexin 1, 2
and 3 individually to determine their binding partners
(figure 4a–c). Based on this analysis, there is strong evidence
that neurexin 1 interacts with 10 proteins including calcium/
calmodulin-dependent serine protein kinase (CASK), leucine-
rich repeat transmembrane neuronal protein 1 (LRRTM1),
LRRTM2, LRRTM3, neuroligin 1, neuroligin 2, neuroligin 3,
neuroligin 4X, SH3 and multiple ankyrin repeat domains
protein 2 (SHANK2) and synaptotagmin-1 with scores of
0.987, 0.983, 0.985, 0.975, 0.998, 0.997, 0.998, 0.997, 0.975,
0.974, respectively. Similarly, neurexins 2 and 3 also have 10
interactors each. There is strong evidence that neurexin 2
interacts with CASK, discs large homologue 4 (DLG4),
LRRTM1, LRRTM2, LRRTM3, neuroligin 1, neuroligin 2, neu-
roligin 3, neuroligin 4X and SHANK2 with scores of 0.979,
0.977, 0.984, 0.983, 0.972, 0.998, 0.998, 0.998, 0.997 and
0.969, respectively. There is strong evidence that neurexin 3
interacts with CASK, DLG4, LRRTM1, LRRTM2, LRRTM3,
neuroligin 1, neuroligin 2, neuroligin 3, neuroligin 4X and
SHANK2 with scores of 0.978, 0.971, 0.979, 0.983, 0.971,
0.998, 0.997, 0.997, 0.997 and 0.969, respectively. The





















Figure 4. Protein interacting partners of neurexins 1–3. (a–c) STRING network of neurexins 1–3. Nodes represent gene-encoded proteins. Edges represent protein–
protein associations. Connections between nodes represent the relationship between proteins. A bold line implies a higher confidence level. (d ) GeneMANIA network
of all three neurexins. Nodes represent gene-encoded proteins. Larger nodes indicate higher protein scores. Edges represent protein–protein associations. Connections








































interacting proteins with very high confidence scores since
the lowest score across the analyses was 0.969. This means
that there is strong experimental evidence that these proteins
interact with one or more of the neurexins.
Analysis of the identified neurexin binding partners
revealed many proteins important in the maintenance and
functioning of synapses. Notably, variants in several of
these proteins are implicated in neuropsychiatric and devel-
opmental disorders. Variants in neuroligin 1 and SHANK2
have been implicated in susceptibility to autism [23,24],
while variants in neuroligin 3 have been implicated in Asper-
ger syndrome and autism [25]. Variants in neuroligin 4X have
been implicated in X-linked forms of Asperger syndrome,
autism susceptibility and mental retardation [25–27]. Variants
in CASK have been implicated in FG syndrome 4, an X-linked
genetic disorder and mental retardation [28–32], variants in
DLG4 have been implicated in intellectual developmental
disorder 62 [33,34] and variants in synaptotagmin-1 have
been implicated in Baker–Gordon syndrome [35].
Furthermore, binding partners of these proteins as well as
the pathways they occur in could also give insight into the
development of disease. CASK binds to amyloid precursor
protein and neuroligin 1 binds to amyloid-β, both of which
are important in AD. LRRTM3 is also a known positive reg-
ulator of amyloid-β formation. Notably, LRRTM3 may be
considered a candidate gene for late-onset AD as it promotes
the processing of amyloid precursor protein which leads to
toxic amyloid-β accumulation [36]. DLG4 is involved in
dopamine receptor binding and synaptotagmin-1 regulates
dopamine secretion. The loss of dopamine functioning is cru-
cial in PD. Indeed, DLG4 is involved in several pathways ofneurodegeneration (in multiple diseases), the HD pathway
as well as cocaine addiction.
3.2. GeneMANIA
GeneMANIA analysis was performed on the neurexins to
reveal further potential protein–protein interactions (figure 4d;
electronic supplementarymaterial, table S1).We performed the
analysis by selecting only proteins with stronger evidence of
neurexin interactions, such as interactions with physical evi-
dence, and evidence from co-expression and co-localization
studies.
All of the binding partners observed by STRING analysis
were still present; however, more interacting proteins were
also identified. These proteins have more diverse functions
but still function in overall synapse maintenance.
This analysis further identified afadin (AFDN), Rho
GTPase activating protein 10 (ARHGAP10), cerebellin 1
(CBLN1), dystroglycan (DAG1), microtubule actin cross-link-
ing factor 1 (MACF1), neurexophilin-2, neurexophilin-3, PDZ
domain-containing protein 2 (PDZD2), proteolipid protein 1
(PLP1), syndecan binding protein 1 (SDCBP), SDCBP2, SH3
domain-containing GRB2-like protein 2 (SH3GL2), signal-
induced proliferation-associated 1-like protein 1 (SIPA1L1),
synaptotagmin-13 (SYT13) TAFA chemokine-like family
member 1 (TAFA1), TUBB-like protein 1 (TULP1) and XK-
related protein 4 (XKR4) as interactors of one or more
neurexin proteins. AFDN, ARHGAP10, MACF1 and
SIPA1L1 are all involved in actin filament binding/
organization, while PDZD2, SDCBP and SDCBP2 are








































Dysregulation of any of these proteins could thus affect cell
adhesion and binding at the synapse. In addition, variants
in MACF1 have been implicated in lissencephaly 9 with com-
plex brainstem malformation [37]. CBLN1 is essential for
synapse integrity and plasticity and its disruption could
lead to synapse dysfunction. DAG1 has multiple functions,
such as laminin and basement membrane assembly, cell sur-
vival, peripheral nerve myelination, nodal structure and cell
migration. Variants in DAG1 have been implicated in both
type A and type C muscular dystrophy–dystroglycanopathy
[38–41]. Muscular dystrophies are genetic disorders charac-
terized by the degeneration of skeletal muscle. Type C
muscular dystrophy–dystroglycanopathy affects the limb-
girdle area [40], while type C is congenital with brain and
eye anomalies [39]. Neurexophilin-2 and neurexophilin-3
are both ligands for α-neurexins and are involved in the
neuropeptide signalling pathway. Disruption of these pro-
teins could, therefore, affect neurotransmitter release and
the subsequent signalling. PLP1 is the major myelin protein
in the CNS and is important for maintaining the structure
of myelin. Disruption of this protein could, therefore, nega-
tively affect the downstream myelination of neurons, as is
seen in multiple sclerosis (MS). Interestingly, PLP1 is also
involved in the development of the substantia nigra, the
main brain region affected by PD. Therefore, PLP1 alterations
could also lead to disruptions in this brain region. SH3GL2
has been implicated in synaptic vesicle endocytosis, while
synaptotagmin-13may be involved in transport vesicle docking
to the plasmamembrane. Dysregulation of these proteins could
thus affect neurotransmitter functioning. TAFA1 is involved in
the modulation of neural stem cell proliferation and differen-
tiation; therefore, dysregulation of this protein could result in
developmental disorders. TULP1 is required for normal devel-
opment of photoreceptor synapses. Variants in TULP1 are
associated with Leber congenital amaurosis [42,43] and retinitis
pigmentosa [42,44–47]. However, this protein is also involved in
actin filament binding, therefore, its dysregulation could also
affect cell adhesion and binding at the synapse. Not much is
known about XKR4 except that it is involved in apoptosis
during development. Therefore, its dysregulation could also
possibly result in developmental disorders.
GO terms and physiological/pathway information on all
binding partners identified by STRING and GeneMANIA are
available in electronic supplementary material, figure S1 and
table S1.4. Role of neurexins in neuropsychiatric
disorders
Literature-based searches using neurexin as a search term
identified several studies that reported an association of
neurexins in various neuropsychiatric disorders. The main
findings of these studies are reported in table 1 and are
summarized below.
4.1. Human studies
NRXN1 has been well documented for its association with
ASDs [54]. Several genetic analyses of families and popu-
lations of people with ASD have shown that copy number
variations (CNVs) and de novo mutational events at the
NRXN1 locus are enriched in ASD [48,49,51,52,54]. In onestudy, NRXN1 was sequenced in cases of ASD with mental
retardation [50]. Mutations (c.–3G > T in the Kozak region,
c.3G > T at the initiation codon (p.M1), p.R375Q and
p.G378S) were found in the NRXN1β coding region thereby
potentially implicate synapse dysfunction an important
determinant in ASD [50].
The first evidence for a potential role of NRXN2 in ASD
was provided by a report of a frameshift mutation within
NRXN2 exon 12 (c.2733delT) in a boy with ASD and his
father who had severe language delay [57]. This mutation
results in a truncated neurexin 2α protein that lacks the bind-
ing sites for the established post-synaptic binding partners
LRRTM2 and neuroligin 2 [57]. Subsequently, a 21-year-old
man with a clinical phenotype including autistic traits, such
as speech and language deficits and pathological insistence
on routine, was reported to have a 570 kb de novo deletion
of 24 genes at chromosome 11q13.1, including NRXN2 [58].
Using microarray analyses on RNA extracted from brain
tissue,Mirnics et al. [69] did not observe a difference in neurexin
1 expression between schizophrenia (SCZ) and control samples.
However, since then, a link between neurexin 1 and SCZ has
been reported in other studies. One study reported that
NRXN1 deletions are more common in those with SCZ; how-
ever, it also found that there was incomplete penetrance of
these deletions in families with SCZ [72]. Kirov et al. [70]
observed a deletion in an SCZ patient at 2p16.3 that disrupts
NRXN1 and predicted that itwas highly likely to be pathogenic.
Also, NRXN1 deletions were shown to segregate with several
neuropsychiatric disorders in a study of a complex family
[78]. The proband had SCZ and other members of his family
had mental retardation, schizophreniform disorder and affec-
tive disorder [78]. After genotyping the proband and eight
family members, they found two rare deletions upstream of
theNRXN1 gene (2p16.3) that co-segregatewith these disorders
[78]. Notably, this shows that deletions inNRXN1maymanifest
as multiple neuropsychiatric phenotypes.
Angione et al. [64] implicated NRXN1 in epilepsy. They
identified a 2p16.3 deletion in an 8-year-old male patient
diagnosed with epilepsy showing symptoms of myoclonic-
atonic seizures (EMAS) [64]. This deletion included the first
five exons of the NRXN1 gene [64].
NRXN genes may also be involved in treatment response.
In one study, it was found that variants in NRXN1 may affect
the long-term treatment outcome of patients with BD by
modulating the effects of antipsychotics [61]. In a study of
Levetiracetam resistance, an antiepileptic drug, Grimminger
et al. [63] found that neurexin 1 is differentially expressed in
non-responder and responder patients with mesial temporal
lobe epilepsy (mTLE), whereby lower levels of neurexin 1
were observed in responder patients.
4.1.1. Association studies
A genome-wide association study (GWAS) by Liu et al. [51]
specifically examined NRXN1 in an autism cohort of the Chi-
nese Han population and discovered 22 variants that were
associated with ASD. In this cohort, one SNP (rs2303298)
was also significantly associated with a risk of developing
ASD [51]. Furthermore, a GWAS of SCZ in Spain showed
that a NRXN1 single nucleotide polymorphism (SNP)
(rs3850333) was close to the significance threshold [71], while
another GWAS in American patients of European or African


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































response to lurasidone in SCZ patients [76]. Additionally,
an association study on Spanish SCZ patients showed that
missense mutations in NRXN1 may actually protect against
susceptibility to SCZ [73].
In a Taiwanese GWAS study, a significant association
between NRXN3 and BD was found [60]. And finally, an
association study on Australian borderline personality dis-
order (BPD) patients showed that several NRXN3 SNPS
were nominally associated with BPD in heroin-dependent
cases [62].
4.2. In vitro and in vivo models of disease
Functional in vitro and in vivo studies have also found evi-
dence for the roles of neurexins in ASD. Monoamine
oxidase A knockout (KO) mice, which are an animal model
for autism, exhibited downregulated levels of both neurexin
1 and neurexin 2 [55]. Furthermore, mice colonized with
the microbiota of ASD patients showed differential splicing
of NRXN2 [59]. Another animal study showed that changes
in the binding of α-neurexins to N-type calcium channels
could be important for some forms of ASD as it mediates
synaptic inhibition [56]. Finally, a study using ASD patient-
derived induced pluripotent stem cells (iPSCs) and differen-
tiated organoids showed that neurexin 1, 2 and 3 mRNA is
overexpressed in these samples [53].
One study examined neurexins in Fragile X syndrome, a
genetic disorder with features similar to ASD, and character-
ized by the silencing of the FMR1 gene [79]. Individuals
with Fragile X experience a range of neurodevelopmental
problems, such as learning disabilities and cognitive impair-
ment, and males are usually more severely affected. Using
FMR1 KO mice, researchers probed brain sections to deter-
mine the levels of neurexin 1, 2 and 3 [66]. Interestingly,
they found that neurexin 3 mRNA levels are increased in
female mice but decreased in male mice and predicted that
this may help explain the sex difference observed in this
disorder [66].
In an animal study of SCZ, neurexin 1 was found to be
downregulated [75]. This study generated iPSCs from patients
with childhood-onset SCZ, differentiated them into glial cells
and injected the glial cells into mice to form chimeric mice as
a model organism [75]. Interestingly, an in vitro study of SCZ
showed that overexpressing Calveolin-1, a potential thera-
peutic for SCZ, actually increased the levels of neurexin 1 as
well as other proteins involved in synaptic plasticity [74].
Neurexin 2α has been implicated in epilepsy and, more
specifically, in seizures. Researchers observed an increase in
neurexin 2α expression in the dentate gyrus of the hippo-
campus in an induced-seizure mouse model [65]. Finally, in
one study, a rat chronic mild stress model of depression
was used to determine if neurexin expression was altered in
major depressive disorder; however, no change in neurexin
1, 2 or 3 levels was observed [67].
So far, there have been two studies validating the effect of
NRXNs in vitro, both by Pak et al. [68,77]. These studies cul-
tured human stem cells as well as mice cells generated from
NRXN1 KO mice. The first study introduced two conditional
NRXN1 mutations previously seen in a range of neuropsy-
chiatric disorders, including ASD and SCZ, into human
embryonic stem cells (hESCs) using adeno-associated virus
recombination and differentiated them into human-induced
neurons (iNs) [68]. These cells were compared to corticalneurons generated from NRXN1α KO mice [68]. The second
study generated iPSCs from three NRXN1 deletion SCZ
patients and three controls, and again differentiated them
into human iNs [77]. These cells were compared to mouse
embryonic stem cells (mESCs) from NRXN1 KO mice [77].
Both studies showed that heterozygous NRXN1 deletions
were able to impair neurotransmitter release and synaptic func-
tion, and increase the levels of the synaptic scaffolding protein,
CASK, in human iNs but not in mice cells [68,77]. Therefore,
these studies provide evidence that NRXN1 deletions exhibit
a major synaptic transmission phenotype in humans and are
thus meaningful at a pathophysiological level.
In summary, these studies demonstrate a link between
NRXNs and neuropsychiatric disorders such as ASD and
SCZ, especially involving full or partial deletions of these
genes. NRXNs have also been associated with BD and BPD.
In addition, protein expression studies have shown changes
in neurexin expression in animal models of epilepsy/seizures
and Fragile X syndrome.5. Role of neurexins in neurodegenerative
disorders
Additionally, literature-based searches provided proof for the
involvement of neurexins in various neurodegenerative dis-
orders, and these studies are listed in table 2 and discussed
below.
5.1. Human studies
Studies examining cerebrospinal fluid (CSF) from AD patients
have observed lowered expression of neurexin 1 [81], as well as
neurexin 2α and neurexin 3α [85]. In addition, it was found that
these changes precede the neurodegeneration markers as they
were observed in the preclinical stage 1 of AD [85]. Moreover,
Aβ42 fibrils in CSF were found to bind to neurexin 1, 2 and 3 as
well as proteoglycans and growth factors [83]. Levels of the
synaptic proteins neuronal pentraxin 2 (NPTX2), GluA4-
containing glutamate (AMPA4), neuroligin 1 and neurexin 2α
are also declined in plasma neuron-derived exomes and this
decline was associated with AD progression [82]. Neurexin 3
protein expression has also been seen to be specifically
downregulated in blood samples of AD patients [84].
Another expression analysis on CSF from MS patients
identified neurexin 2α levels as a potential biomarker for the
disorder [98], while a genetic analysis found that a mutant
miRNA, MIR8485, overexpresses neurexin, which leads to a
calcium overload in pre-synapses [99]. It was hypothesized
that this could induce neurodegeneration in MS [99].
A study examining gene expression in brain tissue
samples of patients with PD found that genes related to
nerve function, such as protocadherin-8 (PCDH8) and neur-
exin 3, were downregulated [109].
Two studies on mild cognitive impairment (MCI) found
promising results.MCI is amilder formof dementia that is con-
sidered the intermediate state of cognitive decline between
normal ageing and dementia [114]. Berchtold et al. [95] found
that neurexin 1 and neurexin 2 are upregulated in MCI. In
addition, neurexin 1 expression was found to be associated
with longitudinal phenotypes in MCI, but not in AD [96].
One study examined neurexins in order to identify genes

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































microarray study showed that neurexin 1 is downregulated in
HIV encephalitis.
Finally, González-Velasco et al. [92] showed that neurexin
2 and neurexin 3 mRNA levels are downregulated in ageing.
Another study found that neurexin 1, 2 and 3 underwent
altered expression in both AD and ageing [86]. A more
recent study from the same group confirmed decreased
expression of both neurexin 1 and neurexin 3 in AD and
ageing [88]. Interestingly, they also found that late-life phys-
ical activity is associated with increased expression of these
proteins [88].
5.1.1. Association study
A GWAS performed by Stein et al. [80] showed that the SNP
rs7155434 within NRXN3 is associated with temporal lobe
structure in AD patients. Temporal lobe volume deficits are
a known risk factor for AD; therefore, this study potentially
implicates NRXN3 with AD risk [80].
5.2. In vitro and in vivo models of disease
Several studies involving cell culture and/or rodent disease
models have also shown differences in the expression of neur-
exin proteins. Three studies showed that neurexin 1 is
downregulated in PD. One of these measured neurexin 1
mRNA in two 6-OHDA (6-hydroxydopamine)-induced cell
culture models; one using human neuroblastoma (SH-SY5Y)
cells and the other using primary mouse mesencephalic cells
[107]. The other studies used a 6-OHDA-induced rat model of
PD and both saw a decrease in neurexin 1 in the striatum
[110,112]. In addition, these studies showed that treatment
with apelin-13 [112] or allopregnanolone [110] is able to attenu-
ate this change. Apelin-13 is an endogenous ligand forAPJ [115]
that has been investigated as a potential protective neuropep-
tide due to the role of the apelin-APJ system in neuronal
survival [116], while allopregnanolone is a reduced metabolite
of progesterone [117] and has reduced CSF levels in PD patients
[118]. Freeze et al. [111], however, noted that the expression
pattern of neurexin 1 does not predict regional atrophy in PD.
This suggests that neurexin 1 is not a marker for PD; however,
it does not exclude it as an important protein in PD patho-
genesis. Another study in PD-transgenic mice overexpressing
α-synuclein found that neurexin 2 expression was also upregu-
lated [108]. In addition, chronic administration of cholesterol
oximes was able to increase the transcription of cytoprotective
genes and undo transcriptome alterations, including the
alteration of neurexin 2 expression [108].
Two studies using induced models of MS implicated neur-
exins in this disorder. One study induced experimental
autoimmune encephalomyelitis (EAE) in rats and observed
downregulation of neurexin 3 [97]. This is a commonly used
model that mimics certain aspects of MS. The other study
used an in vitro model of MS, cultured human monocytes,
and observed an association between ceramide-induced
hypermethylation of DNA and neurexin 1 mRNA [100].
An animal study performed by Neuner et al. [87] showed
that neurexin 3 is downregulated in AD-transgenic mice, but
not in normal aged mice with impaired memory. However,
Popesco et al. [89] found that neurexin 3 is downregulated
in the cerebellum of aged mice. Another study found that
levels of both neurexin 1 and neuroligin 3 are differentially
expressed in cerebral cortex and hippocampus of mice andthat these expression levels change during different stages
of ageing [91]. They predicted that this may be responsible
for the changes in synaptic plasticity observed with age
[91]. Finally, a DNA methylation study by Tserel et al. [90]
showed that CpG sites associated with NRP1, NRXN2 and
miR-29b-2 are hypomethylated in monocytes during ageing.
To date, only one study has examined neurexins in amyo-
trophic lateral sclerosis (ALS) and spinal muscular atrophy
(SMA). In a cell culture model of ALS, neurexin 1 and other
RNA targets of TDP-43 were dysregulated [93]. TDP-43 is a
component of the cytoplasmic inclusion bodies present in
ALS patients [93]. Fragments of TDP-43 are ubiquitinated,
hyperphosphorylated and then accumulate in neurons and
glia [119]. In zebrafish and mouse KO models of SMA, the
SMN-deficiency downregulated neurexin 2α expression and
altered its splicing [113]. SMA is associated with mutation
or deletions in the SMN gene [120] and lack of the SMN
protein causes degeneration and results in anterior horn
cell dysfunction.
5.3. Models of induced neurodegeneration and toxicity
Several studies investigated neurexins in models of
neurodegeneration or toxicity instead of studying a specific
neurodegenerative disease.
Four studies examined the role of neurexins in models of
induced neurodegeneration. Two of these studies hypothesized
that neurexin 1 could play a role in neurodegeneration. The first
study showed that a novel TDP-43 binding miRNA, miR-NID1
(miR-8485) is able to repress neurexin 1 and predicted that this
could play a role in neurodegeneration [103]. Xiang et al. [104]
found in vitro that excessive glycosylated acetylcholinesterase
could competitively disrupt the neurexin 1β-neuroligin junc-
tions and impair the integrity of glutamatergic synapses,
which could lead to neurodegeneration. The other two studies
showed that neurexin 3 is downregulated in animal models of
neurodegeneration [101,102]. Suh et al. [102] saw that neurexin
3 was downregulated in the hippocampus of mice treated with
kainic acid, an inducer of neurodegeneration, while Swanberg
et al. [101] found that neurexin 3 is downregulated in rats
with axonal damage caused by ventral root avulsion.
Two studies were conducted in animal models of neuro-
toxicity. One study exposed zebrafish to chronic, low levels
of the neurotoxin domoic acid and saw an upregulation of
neurexin 2α after two weeks [106]. The other study exposed
rats to acute doses of sarin, which caused a persistent down-
regulation of neurexin 1β and breakdown of the blood–brain
barrier [105].
In summary, multiple studies have shown changes in
neurexin expression in AD, ALS, MS, PD and SMA. Many
of these studies have observed downregulation of protein
expression for neurexin 1, 2 and 3 in these disorders. Simi-
larly, downregulation of neurexin 1, 2 and 3 were observed
in disorders such as HIV encephalitis and MCI and in studies
on ageing, in models of neuronal toxicity, and animal models
of MS and ALS.6. Concluding remarks
A clear link between synaptic dysfunction and neurodegenera-
tive as well as neuropsychiatric disorders has been established








































studies that have linked CNVs, deletions or expression changes
in neurexins to different disorders. The evidence is most com-
pelling for a role of neurexins in neuropsychiatric disorders,
particularly in regard to the involvement of neurexin 1 in
ASD and SCZ. Currently, there is comparatively less evidence
for the involvement of neurexins in neurodegenerative dis-
orders. Although there have been some studies that have
suggested that neurexins may be important in these disorders,
at this stage more experimental data are still needed to draw
concrete conclusions. Therefore, it is apparent that more tar-
geted studies in various disorders involving these genes as
well as the proteins they encode are warranted. In terms of
their broader biological and physiological functions, the neur-
exins function as molecular inducers, are involved in iron and
protein binding, and play a role in cell-to-cell communication
and response to stimuli, consequently making them critical
for normal cell functioning. Furthermore, these proteins interact
with various other proteins such as the neuroligins and the
LRRTM proteins identified via protein interaction networks.
This implicates the neurexins’ involvement in synaptic integrity
and functioning making them promising candidates as disease
genes for a wide range of brain pathologies.
In summary, this review serves to highlight the potential
importance of the neurexin genes and proteins in human dis-
ease and recommends that more targeted studies on these
genes and proteins are warranted. Furthermore, with the
wealth of exomic and genomic sequences and genome-wide
transcriptomic datasets now available, it has become plausibleto interrogate them for their involvement in various human
disorders, on a scale not previously possible. In addition, the
human neurexin protein structures urgently need to be
solved to understand the function and infer accurate protein–
protein interactions as well as to understand the effect of
mutations on the protein structure. Ultimately, improved
knowledge on synapses and their individual components are
necessary to develop novel therapeutic approaches for the
emerging and exciting field of synaptopathies.
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